Ampersand Capital Partners has completed the sale of Tjoapack, a pharmaceutical contract packaging organisation, to Alcami Corporation, a contract development and manufacturing organisation (CDMO).

Tjoapack provides packaging and supply chain services to pharmaceutical and biotechnology companies and has expanded in recent years from its Netherlands base into the US market.

Ampersand acquired the company in 2020 and supported its growth into a transatlantic platform through organic expansion and acquisitions, including Pharma Packaging Solutions in 2021, which established a US packaging presence.

During its ownership period, Ampersand backed investments in expanded facility capacity in Etten Leur, the Netherlands, alongside increased automation and packaging capabilities for complex products, including injectables.

David Parker, general partner at Ampersand Capital Partners, said: “Tjoapack is a compelling example of Ampersand’s strategy in action.

“We identified a founder owned and built business with a strong reputation in the European market, and we partnered with management to build a more global platform by expanding into the US market.”

He added that the company is positioned for continued growth following its integration into Alcami.

Dexter Tjoa, chief executive officer of Tjoapack, said: “Ampersand has been an invaluable partner as we scaled Tjoapack into a global organisation.

“Their support enabled our US expansion and sustained investment in the capabilities that matter to our customers. Joining Alcami is a logical next step in the company’s development.”

The deal reflects ongoing consolidation in the pharmaceutical contract manufacturing and packaging sector, where CDMOs are expanding capabilities and geographic reach to meet increasing demand from global pharma and biotech customers.